121 related articles for article (PubMed ID: 17176074)
1. A phosphoproteomic analysis of the ErbB2 receptor tyrosine kinase signaling pathways.
Mukherji M; Brill LM; Ficarro SB; Hampton GM; Schultz PG
Biochemistry; 2006 Dec; 45(51):15529-40. PubMed ID: 17176074
[TBL] [Abstract][Full Text] [Related]
2. Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment.
Nagano K; Shinkawa T; Mutoh H; Kondoh O; Morimoto S; Inomata N; Ashihara M; Ishii N; Aoki Y; Haramura M
Proteomics; 2009 May; 9(10):2861-74. PubMed ID: 19415658
[TBL] [Abstract][Full Text] [Related]
3. Copine-III interacts with ErbB2 and promotes tumor cell migration.
Heinrich C; Keller C; Boulay A; Vecchi M; Bianchi M; Sack R; Lienhard S; Duss S; Hofsteenge J; Hynes NE
Oncogene; 2010 Mar; 29(11):1598-610. PubMed ID: 20010870
[TBL] [Abstract][Full Text] [Related]
4. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
Kunz C; Borghouts C; Buerger C; Groner B
Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
[TBL] [Abstract][Full Text] [Related]
5. Phosphoproteome profiling of human skin fibroblast cells in response to low- and high-dose irradiation.
Yang F; Stenoien DL; Strittmatter EF; Wang J; Ding L; Lipton MS; Monroe ME; Nicora CD; Gristenko MA; Tang K; Fang R; Adkins JN; Camp DG; Chen DJ; Smith RD
J Proteome Res; 2006 May; 5(5):1252-60. PubMed ID: 16674116
[TBL] [Abstract][Full Text] [Related]
6. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
[TBL] [Abstract][Full Text] [Related]
7. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.
Kim KK; Lee JJ; Yang Y; You KH; Lee JH
Carcinogenesis; 2008 Apr; 29(4):704-12. PubMed ID: 18258606
[TBL] [Abstract][Full Text] [Related]
8. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.
Rush J; Moritz A; Lee KA; Guo A; Goss VL; Spek EJ; Zhang H; Zha XM; Polakiewicz RD; Comb MJ
Nat Biotechnol; 2005 Jan; 23(1):94-101. PubMed ID: 15592455
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel phosphoproteins in signaling pathways triggered by latent membrane protein 1 using functional proteomics technology.
Yan G; Li L; Tao Y; Liu S; Liu Y; Luo W; Wu Y; Tang M; Dong Z; Cao Y
Proteomics; 2006 Mar; 6(6):1810-21. PubMed ID: 16470631
[TBL] [Abstract][Full Text] [Related]
10. Memo mediates ErbB2-driven cell motility.
Marone R; Hess D; Dankort D; Muller WJ; Hynes NE; Badache A
Nat Cell Biol; 2004 Jun; 6(6):515-22. PubMed ID: 15156151
[TBL] [Abstract][Full Text] [Related]
11. Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: implications for adjuvant use of kinase-inhibitory drugs.
Lim YP; Wong CY; Ooi LL; Druker BJ; Epstein RJ
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3980-7. PubMed ID: 15217928
[TBL] [Abstract][Full Text] [Related]
12. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Chen FL; Xia W; Spector NL
Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
[TBL] [Abstract][Full Text] [Related]
14. Tracking and quantification of 32P-labeled phosphopeptides in liquid chromatography matrix-assisted laser desorption/ionization mass spectrometry.
Tuerk RD; Auchli Y; Thali RF; Scholz R; Wallimann T; Brunisholz RA; Neumann D
Anal Biochem; 2009 Jul; 390(2):141-8. PubMed ID: 19376078
[TBL] [Abstract][Full Text] [Related]
15. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
Jani JP; Finn RS; Campbell M; Coleman KG; Connell RD; Currier N; Emerson EO; Floyd E; Harriman S; Kath JC; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Ralston S; Rossi AM; Steyn SJ; Wagner L; Winter SM; Bhattacharya SK
Cancer Res; 2007 Oct; 67(20):9887-93. PubMed ID: 17942920
[TBL] [Abstract][Full Text] [Related]
16. Phosphoproteome analysis of HeLa cells using stable isotope labeling with amino acids in cell culture (SILAC).
Amanchy R; Kalume DE; Iwahori A; Zhong J; Pandey A
J Proteome Res; 2005; 4(5):1661-71. PubMed ID: 16212419
[TBL] [Abstract][Full Text] [Related]
17. Prolonged EGFR signaling by ERBB2-mediated sequestration at the plasma membrane.
Offterdinger M; Bastiaens PI
Traffic; 2008 Jan; 9(1):147-55. PubMed ID: 17956594
[TBL] [Abstract][Full Text] [Related]
18. Systemic analysis of tyrosine phosphorylated proteins in angiopoietin-1 induced signaling pathway of endothelial cells.
Kim YM; Seo J; Kim YH; Jeong J; Joo HJ; Lee DH; Koh GY; Lee KJ
J Proteome Res; 2007 Aug; 6(8):3278-90. PubMed ID: 17595127
[TBL] [Abstract][Full Text] [Related]
19. Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle.
Daub H; Olsen JV; Bairlein M; Gnad F; Oppermann FS; Körner R; Greff Z; Kéri G; Stemmann O; Mann M
Mol Cell; 2008 Aug; 31(3):438-48. PubMed ID: 18691976
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of protein phosphorylation in pregnant rat uteri using stable isotope dimethyl labeling coupled with IMAC.
Huang SY; Tsai ML; Wu CJ; Hsu JL; Ho SH; Chen SH
Proteomics; 2006 Mar; 6(6):1722-34. PubMed ID: 16470654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
